Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O14770
UPID:
MEIS2_HUMAN
Alternative names:
Meis1-related protein 1
Alternative UPACC:
O14770; A6NJI5; A8MWD5; B3KP98; B3KPQ6; Q96DI2; Q96KI4; Q96KI5; Q9NRS1; Q9NRS2; Q9NRS3
Background:
Homeobox protein Meis2, also known as Meis1-related protein 1, plays a pivotal role in transcriptional regulation. It forms complexes with HOX or PBX proteins, stabilizing homeoprotein-DNA complexes. Its involvement spans from pancreatic acinar cells' transcriptional activation to myeloid differentiation and dopamine receptor DRD1 transcription activation.
Therapeutic significance:
Meis2's association with 'Cleft palate, cardiac defects, and impaired intellectual development' underscores its therapeutic potential. Understanding Meis2's role could lead to novel interventions for this autosomal dominant disease, highlighting the importance of targeted gene therapy in congenital malformations and intellectual disabilities.